Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51

Rashi Yadav 1, Lukai Zhai 1,2, Nitesh K. Kunda 3,4, Pavan Muttil 3 and Ebenezer Tumban 1,5,*

Abstract: Three prophylactic vaccines are approved to protect against HPV infections. These vaccines are highly immunogenic. The most recent HPV vaccine, Gardasil-9, protects against HPV types associated with ~90% of cervical cancer (worldwide). Thus, ~10% of HPV-associated cancers are not protected by Gardasil-9. Although this is not a large percentage overall, the HPV types associated with 10% of cervical cancer not protected by the current vaccine are significantly important, especially in HIV/AIDS patients who are infected with multiple HPV types. To broaden the spectrum of protection against HPV infections, we developed mixed MS2-L2 VLPs (MS2-31L2/16L2 VLPs and MS2-consL2 (69-86) VLPs) in a previous study. Immunization with the VLPs neutralized/protected mice against infection with eleven high-risk HPV types associated with ~95% of cervical cancer and against one low-risk HPV type associated with ~36% of genital warts & up to 32% of recurrent respiratory papillomatosis. Here, we report that the mixed MS2-L2 VLPs can protect mice from three additional HPV types: HPV51, which is associated with ~0.8% of cervical cancer; HPV6, which is associated with up to 60% of genital warts; HPV5, which is associated with skin cancers in patients with epidermodysplasia verruciformis (EV). Overall, mixed MS2-L2 VLPs can protect against twelve HPV types associated with ~95.8% of cervical cancers and against two HPV types associated with ~90% of genital warts and >90% recurrent respiratory papillomatosis. Additionally, the VLPs protect against one of two HPV types associated with ~90% of HPV-associated skin cancers in patients with EV. More importantly, we observed that mixed MS2-L2 VLPs elicit protective antibodies that last over 9 months. Furthermore, a spray-freeze-dried formulation of the VLPs is stable, immunogenic, and protective at room temperature and 37 °C.

Keywords: human papillomaviruses; thermostable vaccines; protection; MS2 bacteriophage; virus-like particles; spray-freeze-drying; longevity

1. Introduction

Human papillomaviruses (HPVs) are non-enveloped, double-stranded DNA viruses [1,2]. There are more than 220 different types of HPVs [1,2]. Approximately 40 types are transmitted sexually through anogenital sex or oral sex [3–5]. HPVs are the most common sexually transmitted infections. Infection with high-risk types (HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51–53, 56, 58, 59, 66, 68, 70, 73, and 82) at the anogenital region is associated with anogenital cancers (cervical, vaginal, vulval, penile, and anal cancers). In the oral region, infection is associated with head and neck cancers (oral squamous cell carcinomas, oropharyngeal squamous cell carcinomas, and laryngeal squamous cell carcinomas) [5–8]. On the other hand, infection of the anogenital region with low-risk HPV
types (HPV types 6, 11, 40–44, 54, 61, 72, 81, etc.) is associated with genital warts [5,8].
HPV6 and 11 are associated with ~90% of genital warts. HPV5 and HPV8 are associated
with ~90% of skin cancers in patients with a rare inherited cell-mediated immune skin
disorder (epidermodysplasia verruciformis) [9].

Currently, three prophylactic vaccines (Gardasil-9, Cervarix, and Gardasil-4, discon-
tinued in the U.S.) have been approved to protect against HPV infections. The vaccines
are based on virus-like particles (VLPs) derived from the expression of the major capsid
protein, L1 [10]. L1-based VLPs vaccines are highly immunogenic; however, they protect
mostly against the HPV types included in the vaccines [11]. For example, Gardasil-9 (the
most recent HPV vaccine) offers protection mostly against HPV types included in the
vaccine. It protects against seven HPV types (16, 18, 31, 33, 45, 52, and 58) associated
with approximately 90% of cervical cancers worldwide and against two HPV types (6 and
11) associated with approximately 90% of genital warts [8]. Thus, vaccinated individuals,
especially HIV/AIDS patients (normally infected with multiple HPV types), can still be
infected with HPV types not included in the vaccines [8]. Vaccinated individuals are
advised to continue screening for HPV-associated cancers. There is, therefore, a need for
an improved HPV vaccine: one that can protect against more HPV types.

The HPV capsid is made up of two capsid proteins: the major capsid protein (L1)
and the minor capsid protein (L2). The capsid proteins assemble to form a virus particle
or VLP as follows: first, the L1 protein forms pentamers, and the L2 protein is inserted
(partially buried) at the vertex of each pentamer. Seventy-two copies of the pentamers
then assemble to form a virus particle or VLP [12]. During HPV infection, the L1 protein
makes contact with heparin sulfate proteoglycans on the basement membrane. This leads
to a conformational change, and the L2 protein is transiently exposed to the surface, thus
allowing the virus to bind to receptors on epithelial cells [11,13,14]. The L2 protein is highly
conserved among different HPV types, unlike the L1 protein. Thus, candidate vaccines
targeting the L2 protein are broadly protective. Studies including those from our group
show that immunization with L2 peptides protects against diverse HPV types [15–19].
In our previous works [15,20], we demonstrated that immunization with a mixture of
bacteriophage MS2 VLPs (MS2-31L2/16L2 VLPs and MS2-consL2 (69-86) VLPs [20]) offered
protection against genital and oral infection with HPV pseudoviruses (PsVs) representing
HPV11, 16, 18, 31, 33, 45, 53, 56, and 58 (at the genital region) and HPV16, 35, 39, 52, and 58
(in the oral region). Because low- and middle-income countries are significantly affected
by HPV infection and because they have an underdeveloped cold-chain infrastructure for
storing and distributing vaccines, we formulated mixed MS2 VLPs into a thermostable
vaccine to address the cold-chain challenge. We demonstrated that mixed MS2-L2 VLPs
could be spray-freeze-dried (SFD) into a thermostable product and that the SFD VLPs were
immunogenic. In the current study, we assessed: (i) whether non-SFD-mixed MS2-L2 VLPs
(MS2-31L2/16L2 VLPs and MS2-consL2 (69-86) VLPs) can protect against additional HPV
types (HPV5, 6, and 51), (ii) whether SFD-mixed MS2-L2 VLPs are thermostable at room
temperature for 6 months and at 37 °C for 2 months, and (iii) the longevity of protection
(against HPV51) following immunization with the mixed MS2-L2 VLPs.

2. Materials and Methods
2.1. Production of MS2-L2 VLPs

Plasmids encoding recombinant MS2-L2 proteins have previously been described
(Figure 1) [15]. The plasmids encode proteins for: (i) MS2-31L2/16L2 VLPs (i.e., MS2
coop protein with the insertion of a concatamer of HPV L2 containing amino acids (aa)
20-31 from HPV31 L2 and aa 17-31 from HPV16 L2) and (ii) MS2-consL2 (69-86) (i.e., MS2
coop protein with an insertion of a consensus HPV L2 epitope, aa 69-86). C41 Escherichia coli
bacteria were separately transformed by heat shock with the two recombinant plasmids
(expressing MS2-31L2/16L2 VLPs and MS2-consL2 (69-86) VLPs). Cultures of transformed
bacteria were grown at 37 °C until an optical density (OD)_{600} of 0.6, and the cultures were
induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside for 3 h. The bacteria were
pelleted and lysed with 0.2% lysozyme solution (for MS2-L2 consL2 (69-86)) or 10 mM borax solution (for MS2-31L2/16L2 VLPs). The VLPs were precipitated using 50% (w/v) ammonium sulfate and purified by gel filtration using Sepharose CL-4B columns.

2.2. Thermostability of SFD MS2-L2 VLPs

Spray-freeze-dried MS2 VLPs or mixed MS2-L2 VLPs powders (filled in capsules without adjuvants) have previously been described [20]. Briefly, the VLPs were formulated as follows: mixed MS2-L2 VLPs or control MS2 VLPs were added to a 3% w/v MTDL excipient solution, which contained mannitol (M, 75% w/w), trehalose (T, 7.5% w/w), dextran (D, 2.5% w/w), and L-leucine (L, 15% w/w). The VLPs were added at a concentration of 8% w/w to the MTDL excipients, and the VLPs-excipients were then spray-freeze-dried (SFD) [20]. SFD VLPs were loaded into capsules and stored in sealed bottles at room temperature for 6 months or at 37 °C for 2 months. Following these time points, the powders were reconstituted in 1X phosphate-buffered saline (PBS), and the integrity of VLPs was assessed by transmission electron microscopy (TEM) as follows: VLPs were adsorbed on carbon-coated glow-discharged copper grids for 2 min and were negatively stained with 2% uranyl acetate for 2 min. VLPs were visualized using an FEI 200 KV Titan Themis S-TEM (FEI now ThermoFisher, Waltham, MA, USA) and images were taken at 40,000X. The immunogenicity of the reconstituted VLPs was determined by immunizing mice as described below.

2.3. Immunization of Mice and Assessing Antibody Responses

Animal work was conducted following Michigan Technological University Institutional Animal Care and Use Committee guidelines (Protocol Number: L0264). Groups of 5 female BALB/c mice were immunized intramuscularly with 10 μg of mixed MS2-L2 VLPs (5 μg each of MS2-31L2/16L2 VLPs and MS2-consL2 (69-86)) in the presence of alum hydroxide (Alhydrogel, San Diego, CA, USA). 10 μg amounts of reconstituted SFD-mixed MS2-L2 VLPs stored at room temperature or 37 °C were also used to immunize mice in the presence of alum hydroxide. Control mice were immunized with 10 μg each of Gardasil-9, MS2 VLPs, and spray-freeze-dried MS2 VLPs (with alum). All immunizations were performed twice at two-week intervals. To assess the longevity of immune responses, 6 female BALB/c mice were immunized, thrice, with 10 μg of mixed MS2-L2 VLPs with alum at two-week intervals. The mice were immunized thrice because the concentration of each of the L2 VLP in the mixture of VLPs was only 5 μg. Whole blood was collected 2 weeks after the last immunizations (to assess antibody titers in sera) except from the groups of mice that were immunized with VLPs for longevity studies. In these groups of mice, sera were collected monthly. IgG antibody titers in sera were conducted by peptide enzyme-linked immunosorbent assay (ELISA) using the following peptides as target antigens: (i) 16L2 peptide, (ii) 31L2 peptide, and (iii) HPV consL2 (69-86) [21]. Briefly, 96-well plates were coated with 500 ng of peptide conjugated to streptavidin or biotin. The plates were blocked for 2 hours with 0.5% nonfat milk in 1X PBS. Sera from immunized mice were

![Figure 1. Plasmids with L2 sequences that were used for protein expression. 31L2/16L2 sequence (A) and consL2 (69-86) sequence (B) were inserted into plasmid by polymerase chain reaction in a previous study [15].](image-url)
serially diluted (4-fold) and were added to the coated ELISA plates for 2 h. The plates were washed with 1X PBS, and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibodies (1:5000 dilution) were added for 1 hours. The wells were washed and developed with TMB solution (3, 3′, 5, 5′-tetramethylbenzidine). The reaction was stopped with 1 M hydrochloric acid. Absorbance was measured at OD\textsubscript{450nm} using the Synergy LX multimode reader (BioTek, Winooski, VT, USA). Antibody titers were determined by considering the reciprocal of the highest sera dilutions at which the reactivity of experimental sera was greater than 2-fold compared to control sera at the same dilution.

2.4. Genital Infection

HPV pseudoviruses (PsVs) representing HPVs 5, 6, and 51 were made and purified by cesium chloride gradient ultracentrifugation as described previously [22,23]. In brief, PsVs were made by co-transfecting 293TT cells with equal concentrations of pSheLL plasmid and pClucf plasmid. pSheLL plasmid expresses the capsid proteins of the HPV type for the pseudovirus of interest, while pClucf plasmid expresses two reported proteins (luciferase and green fluorescence protein). Two days after transfections, the cells were harvested and lysed, and the lysates were incubated overnight at 37 °C to allow the PsVs to mature. The lysates were spun down, and the supernatant was put on a discontinuous cesium chloride gradient (1.25 and 1.4 g/mL, w/v). The gradient was spun for 17 h (4 °C) at 20,000 rpm, and a band corresponding to HPV PsVs was collected. HPV PsVs contain pClucf plasmids, which can be used to assess infectivity based on the expression of the reporter genes (luciferase and green fluorescence protein) in infected cells. Infection studies were conducted as previously described [22,24,25]. Concisely, immunized mice were subcutaneously injected with 3 mg of Depo-Provera. Five days after Depo-Provera treatment, the genitals of mice were treated with 4% nonoxynol-9, and the mice were vaginally challenged (5 h later) with ~6.4 × 10\textsuperscript{6} infectious units (IUs) of PsVs as described previously. Forty-eight hours after PsV infection, mice were genitally instilled with 0.4 mg of luciferin (a substrate for luciferin). Mice were imaged using IVIS Spectrum at one-minute exposure to capture the intensity of luciferase expression (bioluminescence, which is indicative of the level of infection). Average radiance (p/cm\textsuperscript{2}/sr) was determined by drawing equally sized regions of interest surrounding the site of PsV administration.

2.5. Statistical Analysis

Statistical analysis of ELISAs and HPV PsV challenge studies were performed using an unpaired two-tailed t-test and an unpaired one-tailed t-test, respectively.

3. Results

3.1. Mixed MS2-L2 VLPs Protect against HPV PsVs 5, 6, and 51

We previously showed that non-SFD-mixed MS2-L2 VLPs are immunogenic [20]. However, to confirm the immunogenicity of the VLPs prior to the protection studies, we performed an ELISA using sera from new groups of immunized mice (to be infected). Figure 2A shows that the antibody titers (>10\textsuperscript{3}) were similar to those from our previous study [20]. High-titer antibodies were elicited against all three L2 peptides tested (16L2 aa 17-31, 31L2 aa 17-31, and consensus L2 69-86). Given the immune responses, we decided to assess whether immunized mice would be protected from genital infection with HPV PsVs 5, 6, and 51. In the genital region, if anti-HPV L2 antibodies were present (due to vaccination), they would block entry of the PsVs into cells in the region, and thus, pClucf would not be delivered into the nuclei for the reporter genes (e.g., luciferase) to be expressed. Luciferase expression is a read-out for infection. However, if anti-L2 antibodies were absent, the PsVs would enter cells in the genital region, leading to the expression of reporter genes in the nuclei. PsV infection is not productive (i.e., the PsVs do not replicate, and thus, they cannot spread from cell to cell). As shown in Figure 2B, mice immunized with the non-SFD-mixed MS2-L2 VLPs were protected against the three HPV PsVs. Mice immunized with non-SFD-mixed MS2-L2 VLPs had low average radiances (luciferase expression...
expression) compared to control mice. Protection against HPV PsV5 was better compared to protection against HPV PsVs 6 and 51.

Figure 2. Immunogenicity of mixed MS2-L2 VLPs with alum. Mice were immunized intramuscularly, twice, with 10 μg of mixed MS2-L2 VLPs or control MS2 VLPs with alum at two-week intervals. (A) Sera were collected 2 weeks after the last immunization, and anti-L2 peptide IgG titers in sera were determined by end-point dilution ELISA using the following peptides as target antigens: HPV16 L2 peptide, HPV31 L2, and HPV consL2 (69-86). (B) The mice in A above were genitally challenged with 6.4 × 10^6 IU of: HPV PsV5, HPV PsV6, and HPV PsV51. The average radiance (p/s/cm^2) of luciferase expression was determined using Living Image software version 4.5.5. Each datum represents the average radiance of an individual mouse, and the lines represent the geometric mean for each group of mice. The p-values were determined by an unpaired two-tailed t-test for 2A and an unpaired one-tailed t-test for 2B.

3.2. Spray-Freeze-Dried Mixed MS2-L2 VLPs Are Thermostable at Room Temperature for 6 Months and at 37 °C for 2 Months

To assess at what temperature and for how long the SFD-mixed MS2-L2 VLPs can be stored without refrigeration, the SFD VLPs were stored at room temperature for 6 months and at 37 °C for 2 months, and their integrities were assessed using TEM. As shown in Figure 3, spray-freeze-dried VLPs stored at either temperature did not disintegrate. To assess whether the SFD VLPs stored at room temperature or 37 °C were immunogenic, reconstituted spray-freeze-dried VLPs were used to immunize mice. SFD-mixed MS2-L2 VLPs stored at room temperature for 6 months elicited high-titer anti-IgG peptide antibo-
ies against HPV16 L2 and consensus L2 (69-86) peptides, while suboptimal antibodies (in comparison to non-SFD VLPs in Figure 2A) were detected against the HPV31 L2 peptide (Figure 4A). SFD-mixed MS2-L2 VLPs stored at 37 °C for 2 months were also immunogenic (Figure 4B); however, their overall immune responses against two L2 peptides (HPV16 L2 and consL2 (69-86)) were lower compared to the VLPs that were stored at room temperature or non-SFD in Figure 2A. To assess if the elicited immune response (at least $>10^3$) could offer protection against HPV pseudovirus infection, immunized mice were genetically infected with HPV PsV6. As shown in Figure 4C, SFD-mixed MS2-L2 VLPs offered protection. Three out of five mice from the group that was immunized with SFD-mixed MS2-L2 VLPs stored at room temperature (for 6 months) offered protection (similar to Gardasil-9) against HPV PsV6 compared to SFD-mixed MS2-L2 VLPs stored at 37 °C for 2 months. Two mice from the group that was immunized with spray-freeze-dried MS2-L2 VLPs stored at room temperature were not protected at all. Overall, Gardasil-9-immunized mice (refrigerated) offered the best protection compared to the mice immunized with spray-freeze-dried VLPs stored at the above temperatures and time frames.

Figure 3. Transmission electron microscopy (TEM) images of spray-freeze-dried (SFD) VLPs and liquid VLPs. Spray-freeze-dried VLPs were reconstituted in PBS and analyzed using TEM. (A) TEM of SFD-mixed MS2-L2 VLPs (from frozen stock). (B) TEM of spray-freeze-dried control MS2 VLPs stored at room temperature for 6 months. (C) TEM of SFD-mixed MS2-L2 VLPs stored at 37 °C for 2 months. (D) TEM of SFD-mixed MS2-L2 VLPs stored at 37 °C for 2 months. Images were taken at 40,000× magnification.

Figure 4. Cont.
Figure 4. Immunogenicity of SFD-mixed MS2-L2 VLPs and protection from genital infection. Mice were immunized, twice, intramuscularly with 10 µg of spray-freeze-dried VLPs with alum at two-week intervals. Sera were collected 2 weeks after the last immunization. Anti-L2 peptide IgG titers in sera were determined by end-point dilution ELISA using 16L2 peptide, 31L2 peptide, and consL2 (69-86) peptide as target antigens. The sera were derived from mice immunized with: (A) SFD-mixed MS2-L2 VLPs and SFD MS2 VLPs stored at room temperature for 6 months and (B) SFD MS2 VLPs and SFD-mixed MS2-L2 VLPs stored at 37 °C for 2 months. Immunized mice in 3A and 3B, including a positive control group, immunized with 10 µg of Gardasil-9, were genitally challenged with 6.4 × 10^6 infectious units of HPV PsV6 (C). Each datum represents the average radiance of an individual mouse, and the lines represent the geometric mean for each group of mice. The p-values were determined by an unpaired two-tailed t-test for Figure 4A,B and an unpaired one-tailed t-test for Figure 4C.
3.3. Mixed MS2-L2 VLPs Elicit Long-Lasting Antibody Response against PsV51

To assess how long the immune responses elicited by mixed MS2-L2 VLPs would last, mice were immunized with non-SFD-mixed MS2-L2 VLPs, and antibody titers were monitored monthly for 10 months. As shown in Figure 5A–C, antibody titers stayed fairly constant against HPV16 L2 (aa 17-31) and HPV31 L2 (aa 17-31) peptides but minimally declined against consensus L2 (69-86) peptide. More importantly, the mice were protected from infection against HPV PsV51 10 months after immunization (Figure 5D).

![Figure 5](image-url)
4. Discussion

Three prophylactic vaccines are approved to protect against HPV infections. These vaccines are very immunogenic. However, they protect mostly against HPV types included in the vaccines. For example, Gardasil-9, which has the most HPV VLP types (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) included in the vaccines, protects against HPVs associated with ~90% of cervical cancer, 80–85% of HPV-associated vaginal cancer, 85–90% of HPV-associated vulvar cancer, 90–95% of HPV-associated anal cancer, ~90% of genitourinary warts, and ~86% of HPV-associated penile cancer [8]. It is also anticipated that the vaccine will protect against HPV types associated with ~93% of HPV-associated head and neck cancers. The vaccine also protects against approximately 90% of genital warts [8]. Given the fact that the L1-based vaccines do not protect against all HPV types associated with cancers and the fact that most people infected with HPV may be infected with more than one HPV type (especially HIV/AIDS patients), an alternative target for a broadly protective HPV vaccine has been under exploration for many years. For example, the L2 protein has had a lot of attention (within the last two decades) as a target antigen to develop a next-generation vaccine against HPVs [26–29]. Immunization with peptides derived from the N-terminus of L2 elicits antibodies that cross-protect against diverse HPV types [16]. In previous works, we demonstrated that immunization with a mixture of two MS2-L2 VLPs (MS2-31L2/16L2 VLPs and MS2-consL2 (69–86) VLPs) offers protection from genital infection with eight high-risk HPV types (HPV PsV16, 18, 31, 33, 45, 53, 56, and 58) and one low-risk HPV type (HPV PsV11). We also demonstrated that the candidate vaccine can offer protection from oral infection with five high-risk types (HPV PsV16, 35, 39, 52, and 58) [15,20]. Here, we show that the candidate vaccine can protect against three additional HPV types: non-SFD-mixed MS2-L2 VLPs also protect against HPV PsV51 (a high-risk HPV type), HPV PsV6 (a low-risk type associated with genital/oral infection), and HPV PsV5. HPV5 is a low-risk HPV, and it is one of two low-risk HPVs (including HPV8) associated with ~90% of HPV-associated skin cancer in patients suffering from epidermodysplasia verruciformis. Protection against HPV PsV5 was better compared to protection against HPV PsV6 and PsV51. We believe this was because part of HPV16 peptide (amino acid 20–31), which was displayed on one of the VLPs is 100% identical to that of HPV5. This amino acid sequence is only 81–90% identical to those of HPV6 and HPV51. These results are consistent with the reactivity of sera (from mice immunized with HPV16 L2 peptide 17–31) with peptides from HPV5 L2 and HPV6 L2 in our previous study [21].

Current HPV vaccines require cold-chain storage and may not be suitable for developing countries with economic challenges such as expenses to provide continuous refrigeration during transportation and storage. Exposure to aberrant temperature can decrease the efficacy of vaccines (in general) [30]. For example, we have shown that liquid MS2-L2 VLPs disintegrate after storage at room temperature for one month [31]. Hence, a thermostable vaccine will be a better solution to achieve widespread immunization for low- and middle-income countries with less-developed refrigeration facilities. Fortunately, in our previous study, we showed that VLPs are thermostable after spray-freeze-drying. We observed that SFD-mixed MS2-L2 VLPs could be stored at room temperature for 2 months without affecting immunogenicity and protection [20]. Here, we demonstrated that the VLPs could be stored for an additional 4 months (a total of 6 months) at room temperature or 37 °C for 2 months without a significant loss in the integrity of the VLPs. Sera from SFD VLPs stored at room temperature (6 months) had slightly higher reactivity against all HPV L2 peptides (except HPV 31L2) compared to sera from the same VLPs stored at 37 °C (2 months). Although antibody titers in sera from mice immunized with the VLPs stored at room temperature were slightly lower against HPV 31L2 peptide compared to those from VLPs stored at 37 °C, this difference was not significant ($p = 0.1434$) (Figure 4). Three out of five mice that were immunized with the SFD-mixed MS2-L2 VLPs stored at room temperature offered protection against PsV6 that was similar to that of Gardasil-9 but better than those in mice immunized with SFD VLPs stored at 37 °C. However, two mice in the group of SFD-mixed MS2-L2 VLPs stored at room temperature were not protected at all
We are not sure why these two mice were not protected. Systemic immunizations elicit protective immunity at mucosal sites; however, they can also be incapable of eliciting protective mucosal immune responses [32]. We speculate that the two mice might not have had high-titer protective antibodies in the genital region (where the pseudovirus was instilled) despite high-titers in the sera.

In summary, mixed MS2-L2 VLPs are an ideal candidate HPV vaccine that should be explored further. They are highly immunogenic. Non-SFD-mixed MS2-L2 VLPs can protect against HPV PsV5, 6, and 51. This is in addition to protection against HPV PsV11, 16, 18, 31, 33, 35, 39, 45, 53, 56, 52, and 58 in our previous studies [15,20]. Thus, mixed MS2-L2 VLPs have the potential to protect against twelve high-risk HPV types. These HPV types are associated with ~95.8% of cervical cancer [8] and ~99.5% of HPV-associated head and neck cancers [33–36]. Additionally, the mixed MS2-L2 VLPs have the potential to protect against low-risk HPV types (HPV6 and HPV11) associated with ~90% of genital warts and >90% recurrent respiratory papillomatosis. Estimates are based on the contribution of HPV6 and HPV11 in genital warts [37,38] and recurrent respiratory papillomatosis [39,40]. Moreover, immune responses elicited by non-SFD-mixed MS2-L2 VLPs lasted up to 10 months (tested so far) and were protective against HPV PsV51. Given the fact SFD-mixed MS2-L2 VLPs stored at room temperature for 6 months and at 37 °C for 2 months offered suboptimal protection from HPV PsV6, we recommend that the spray-freeze-dried VLPs should only be stored at room temperature for 2 months. SFD-mixed MS2-L2 VLPs stored at room temperature for 2 months offered complete protection from infection in our previous study [20]. Thus, they can be reconstituted on-site just prior to immunization. Such a candidate vaccine would be applicable in low and middle-income countries that do not have a robust cold-chain infrastructure for storing and distributing vaccines. The candidate vaccine would also be applicable in communities with HIV/AIDS patients, who may be susceptible to infections with multiple cancer-causing HPV types. Future studies are required to assess the longevity of immune responses to the SFD-mixed MS2-L2 VLPs and the immunogenicity of the VLPs in larger animal models such as rabbits or guinea pigs. MS2-16L2 VLPs are immunogenic in rabbits. Sera from rabbits immunized with MS2-16L2 VLPs neutralize HPV PsV16 (unpublished data); thus, it is worth exploring whether the immunization of rabbits with mixed MS2-L2 VLPs will elicit a broad response compared to immunization with only MS2-16L2 VLPs.

**Author Contributions:** R.Y. immunized mice and conducted protection studies, L.Z. developed the expression vectors, N.K.K. formulated the VLPs into dry powder, P.M. and E.T. conceptualized the experiments. R.Y. and E.T. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the US National Institute of Dental and Craniofacial Research, Grant Number 1R15 DE025812-01A1. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Michigan Technological University (protocol number L0264, approved on 18 March 2019).

**Informed Consent Statement:** Not Applicable.

**Data Availability Statement:** Not Applicable.

**Acknowledgments:** We would like to thank Sara Zimmer (University of Minnesota, Duluth) for providing access to IVIS Spectrum equipment. We would also like to thank Owen Mills and Pinaki Mukherjee at Applied Chemical and Morphological Analysis Laboratory at Michigan Tech for help with TEM imaging.

**Conflicts of Interest:** Ebenezer Tumban is a coinventor of L2 bacteriophage virus-like particles-related patent applications licensed to Agilvax Biotech by the University of New Mexico. Interactions with Agilvax Biotech are managed by the University of New Mexico in accordance with its conflict-of-interest policies.
References

1. Burk, R.D.; Harari, A.; Chen, Z. Human papillomavirus genome variants. *Virology* 2013, 445, 232–243. [CrossRef]

2. Chen, Z.; Schiffman, M.; Herrero, R.; DeSalle, R.; Anastas, K.; Segondy, M.; Sahasrabuddhe, V.V.; Gravitt, P.E.; Hsing, A.W.; Chan, P.K.S.; et al. Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). *Virology* 2018, 516, 86–101. [CrossRef]

3. Garland, S.M.; Joura, E.A.; Ault, K.A.; Bosch, F.X.; Brown, D.R.; Castellsague, X.; Ferenczy, A.; Ferris, D.G.; Giuliano, A.R.; Hernandez-Avila, M.; et al. Human papillomavirus genotypes from vaginal and vulvar intraepithelial neoplasia in females 15-26 years of age. *Obstet. Gynecol.* 2018, 132, 261–270. [CrossRef]

4. Shah, A.; Malik, A.; Garg, A.; Mair, M.; Nair, S.; Chaturvedi, P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: A review of the literature. *Postgrad. Med. J.* 2017, 93, 704–709. [CrossRef] [PubMed]

5. Tumban, E. A current update on human papillomavirus-associated head and neck cancers. *Viruses* 2019, 11, 922. [CrossRef] [PubMed]

6. Berman, T.A.; Schiller, J.T. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. *Cancer* 2017, 123, 2219–2229. [CrossRef] [PubMed]

7. Crow, J.M. HPV: The global burden. *Nature* 2012, 488, S2–S3. [CrossRef] [PubMed]

8. Zhai, L.; Tumban, E. Gardasil-9: A global survey of projected efficacy. *Antivir. Res.* 2017, 130, 101–109. [CrossRef]

9. Patel, T.; Morrison, L.K.; Rady, P.; Tyring, S. Epidermodysplasia verruciformis and susceptibility to HPV. *Dis. Markers* 2010, 29, 199–206. [CrossRef]

10. Haghshenas, M.R.; Mousavi, T.; Kheradmand, M.; Afshari, M.; Moosazadeh, M. Efficacy of human papillomavirus L1 protein vaccines (cervaxir and garasil) in reducing the risk of cervical intraepithelial neoplasia: A meta-analysis. *Int. J. Prev. Med.* 2017, 8, 44.

11. Brown, D.R.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.E.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Koutsky, L.A.; Tay, E.H.; Garcia, P.; et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. *J. Infect. Dis.* 2009, 199, 926–935. [CrossRef] [PubMed]

12. Kirnbauer, R.; Booy, F.; Cheng, N.; Lowy, D.R.; Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc. Natl. Acad. Sci. USA* 1992, 89, 12180–12184. [CrossRef] [PubMed]

13. Kines, R.C.; Thompson, C.D.; Lowy, D.R.; Schiller, J.T.; Day, P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. *Proc. Natl. Acad. Sci. USA* 2009, 106, 20458–20463. [CrossRef] [PubMed]

14. Bywaters, S.M.; Brendle, S.A.; Tossi, K.P.; Biryukov, J.; Meyers, C.; Christensen, N.D. Antibody competition reveals surface location of HPV L2 minor capsid protein residues 17–36. *Viruses* 2017, 9, 336. [CrossRef] [PubMed]

15. Zhai, L.; Peabody, J.; Pang, Y.S.; Schiller, J.; Chackerian, B.; Tumban, E. A novel candidate HPV vaccine: MS2 phage VLP containing subdominant, cross-neutralizing epitopes. *Viruses* 2013, 445, 232–243. [CrossRef] [PubMed]

16. Shah, A.; Malik, A.; Garg, A.; Mair, M.; Nair, S.; Chaturvedi, P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: A review of the literature. *Postgrad. Med. J.* 2017, 93, 704–709. [CrossRef] [PubMed]

17. Seitz, H.; Canali, E.; Ribeiro-Müller, L.; Pàfì, A.; Bolchi, A.; Tommasino, M.; Ottonello, S.; Müller, M. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. *Vaccine* 2014, 32, 2610–2617. [CrossRef]

18. Schellenbacher, C.; Roden, R.; Kirnbauer, R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. *J. Virol.* 2009, 83, 10085–10095. [CrossRef]

19. Nieto, K.; Weghofer, M.; Sehr, P.; Ritter, M.; Sedlmeier, S.; Karanbam, B.; Seitz, H.; Muller, M.; Kellner, M.; Horer, M.; et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. *PLoS ONE* 2012, 7, e39741. [CrossRef]

20. Zhai, L.; Yadav, R.; Kunda, N.K.; Anderson, D.; Brickner, E.; Miller, E.K.; Basu, R.; Muttill, P.; Tumban, E. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head and neck cancers and cervical cancer. *Antivir. Res.* 2019, 166, 56–65. [CrossRef]

21. Tumban, E.; Peabody, J.; Peabody, D.S.; Chackerian, B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. *PLoS ONE* 2011, 6, e23310. [CrossRef]

22. Tumban, E.; Peabody, J.; Tyler, M.; Peabody, D.S.; Chackerian, B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. *PLoS ONE* 2012, 7, e49751. [CrossRef]

23. Buck, C.B.; Pastrana, D.V.; Lowy, D.R.; Schiller, J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. *Methods Mol. Med.* 2005, 119, 445–462. [PubMed]

24. Roberts, J.N.; Buck, C.B.; Thompson, C.D.; Kines, R.; Bernardo, M.; Choyke, P.L.; Lowy, D.R.; Schiller, J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. *Nat. Med.* 2007, 13, 857–861. [CrossRef]

25. Johnson, K.M.; Kines, R.C.; Roberts, J.N.; Lowy, D.R.; Schiller, J.T.; Day, P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. *J. Virol.* 2009, 83, 2067–2074. [CrossRef] [PubMed]

26. Roden, R.B.; Yutzy IV, W.H.; Fallon, R.; Inglis, S.; Lowy, D.R.; Schiller, J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. *Virology* 2009, 370, 254–257. [CrossRef] [PubMed]
27. Alphs, H.H.; Gambhira, R.; Karanam, B.; Roberts, J.N.; Jagu, S.; Schiller, J.T.; Zeng, W.; Jackson, D.C.; Roden, R.B. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. *Proc. Natl. Acad. Sci. USA* 2008, 105, 5850–5855. [CrossRef]

28. Pastrana, D.V.; Gambhira, R.; Buck, C.B.; Pang, Y.Y.; Thompson, C.D.; Culp, T.D.; Christensen, N.D.; Lowy, D.R.; Schiller, J.T.; Roden, R.B. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. *Virology* 2005, 337, 365–372. [CrossRef]

29. Jagu, S.; Karanam, B.; Gambhira, R.; Chivukula, S.V.; Chaganti, R.J.; Lowy, D.R.; Schiller, J.T.; Roden, R.B. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. *J. Natl. Cancer Inst.* 2009, 101, 782–792. [CrossRef]

30. Edstam, J.S.; Dulmaa, N.; Tsendjav, O.; Dambasuren, B.; Densmaa, B. Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia. *Prev. Med.* 2004, 39, 384–388. [CrossRef]

31. Tumban, E.; Muttil, P.; Escobar, C.A.; Pebody, J.; Wafula, D.; Pebody, D.S.; Chackerian, B. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. *Vaccine* 2015, 33, 3346–3353. [CrossRef]

32. Su, F.; Patel, G.B.; Hu, S.; Chen, W. Induction of mucosal immunity through systemic immunization: Phantom or reality? *Hum. Vaccin Immunother.* 2016, 12, 1070–1079. [CrossRef]

33. Castellsagué, X.; Alemany, L.; Quer, M.; Halec, G.; Quirós, B.; Tous, S.; Clavero, O.; Alòs, L.; Biegner, T.; Szafarowski, T.; et al. HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. *J. Natl. Cancer Inst.* 2016, 108, djv403. [CrossRef] [PubMed]

34. Kreimer, A.R.; Clifford, G.M.; Boyle, P.; Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. *Cancer Epidemiol. Biomark. Prev.* 2005, 14, 467–475. [CrossRef] [PubMed]

35. Ndiaye, C.; Mena, M.; Alemany, L.; Arbyn, M.; Castellsagué, X.; Laporte, L.; Bosch, F.X.; de Sanjosé, S.; Trottier, H. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. *Lancet Oncol.* 2014, 15, 1319–1331. [CrossRef]

36. de Martel, C.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int. J. Cancer* 2017, 141, 664–670. [CrossRef] [PubMed]

37. Chang, L.; Ci, P.; Shi, J.; Zhai, K.; Feng, X.; Colombara, D.; Wang, W.; Qiao, Y.; Chen, W.; Wu, Y. Distribution of genital wart human papillomavirus genotypes in China: A multi-center study. *J. Med. Virol.* 2013, 85, 1765–1774. [CrossRef]

38. Sturegard, E.; Johansson, H.; Ekstrom, J.; Hansson, B.G.; Johnsson, A.; Gustafsson, E.; Dillner, J.; Forslund, O. Human papillomavirus typing in reporting of condyloma. *Sex. Transm. Dis.* 2013, 40, 123–129. [CrossRef]

39. Omland, T.; Lie, K.A.; Akre, H.; Sandlie, L.E.; Jebsen, P.; Sandvik, L.; Nymoen, D.A.; Bzhalava, D.; Dillner, J.; Brondbo, K. Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. *PLoS ONE* 2014, 9, e99114. [CrossRef] [PubMed]

40. Kocjan, B.J.; Gale, N.; Hočevar Boltežar, I.; Seme, K.; Fujs Komloš, K.; Hošnjak, K.; Maver, P.J.; Jelen, M.M.; Zupanic Pajnič, I.; Balažic, J.; et al. Identical human papillomavirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years. *J. Infect. Dis.* 2013, 207, 583–587. [CrossRef] [PubMed]